Bocidelpar sulfate is under clinical development by Mitobridge and currently in Phase III for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis). According to GlobalData, Phase III drugs for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Bocidelpar sulfate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bocidelpar sulfate overview
MA-0211 is under development for the treatment of Duchenne muscular dystrophy (DMD), mitochondrial myopathies and chronic fatigue syndrome. It is administered through oral route. The drug candidate acts by targeting peroxisome proliferator-activated receptor delta (PPARdelta). It was also under development for Leber’s hereditary optic neuropathy (LHON), fatty acid oxidation disorders including Melas syndrome, Kearns-Sayre syndrome
Mitobridge overview
Mitobridge, formerly Mitokyne, a subsidiary of Astellas Pharma Inc is a drug development company. It discovers and develops small molecule therapeutics that recovers mitochondrial functions. The company develops therapies for rare diseases and expands into more common diseases. Mitobridge utilizes screening platform to identify and develop novel therapeutics. In addition, The company holds expertise in the areas of mitochondrial genetic diseases, musculoskeletal, liver disease, kidney, neurodegenerative disorders and diseases and conditions of aging. It works in collaboration with companies in the field of mitochondrial biology and medicine. Mitobridge is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Bocidelpar sulfate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.